Epiomic Epidemiology Series: Traumatic Spinal Cord Injury Forecast in 15 Major Markets 2016-2026

April 2016 | 62 pages | ID: E6FDF10616EEN
Black Swan Analysis limited

Abstracts

Spinal cord injury is defined as damage to any part of the spinal cord or nerves at the end of the spinal canal, often resulting in permanent changes in strength, sensation and other body functions below the site of the injury. Traumatic spinal cord injury (TSCI) is classified as injury to the spine caused by a traumatic event.

This report provides the current prevalent population for TSCI across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Canada, Netherlands, Australia, South Africa and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains an overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of TSCI have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TSCI include:

• Deep Vein Thromboses (DVT)
• Urinary Tract Infections (UTI)
• Pressure sores
• Neuropathic pain
• Spasticity

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global TSCI’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of TSCI and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on TSCI’s prevalent population.
• Identify sub-populations within TSCI which require treatment.
• Gain an understanding of the specific markets that have the largest number of TSCI patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Traumatic Spinal Cord Injury
  TSCI by Cause
  Location of TSCI
  Level of Impairment of TSCI
  Sequelae of TSCI
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

ASIA grading classification for spinal cord injury
Frankel scale for classification for spinal cord injury
Glasgow Coma Scale for scoring patient response
Prevalence of TSCI, total (000s)
Prevalence of TSCI, males (000s)
Prevalence of TSCI, females (000s)
Cause of TSCI, total (000s)
TSCI patients by location of injury, total (000s)
TSCI patients by ASIA score, total (000s)
TSCI patients with paraplegia, total (000s)
TSCI patients with tetraplegia, total (000s)
TSCI patients with DVT, total (000s)
TSCI patients with UTIs, total (000s)
TSCI patients with Pressure Sores, total (000s)
TSCI patients with Spasticity, total (000s)
TSCI patients with Neuropathic pain, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of TSCI by 5-yr age cohort, males (000s)
USA Prevalence of TSCI by 5-yr age cohort, females (000s)
France Prevalence of TSCI by 5-yr age cohort, males (000s)
France Prevalence of TSCI by 5-yr age cohort, females (000s)
Germany Prevalence of TSCI by 5-yr age cohort, males (000s)
Germany Prevalence of TSCI by 5-yr age cohort, females (000s)
Italy Prevalence of TSCI by 5-yr age cohort, males (000s)
Italy Prevalence of TSCI by 5-yr age cohort, females (000s)
Spain Prevalence of TSCI by 5-yr age cohort, males (000s)
Spain Prevalence of TSCI by 5-yr age cohort, females (000s)
United Kingdom Prevalence of TSCI by 5-yr age cohort, males (000s)
United Kingdom Prevalence of TSCI by 5-yr age cohort, females (000s)
Netherlands Prevalence of TSCI by 5-yr age cohort, males (000s)
Netherlands Prevalence of TSCI by 5-yr age cohort, females (000s)
Turkey Prevalence of TSCI by 5-yr age cohort, males (000s)
Turkey Prevalence of TSCI by 5-yr age cohort, females (000s)
Canada Prevalence of TSCI by 5-yr age cohort, males (000s)
Canada Prevalence of TSCI by 5-yr age cohort, females (000s)
Australia Prevalence of TSCI by 5-yr age cohort, males (000s)
Australia Prevalence of TSCI by 5-yr age cohort, females (000s)
South Africa Prevalence of TSCI by 5-yr age cohort, males (000s)
South Africa Prevalence of TSCI by 5-yr age cohort, females (000s)
Brazil Prevalence of TSCI by 5-yr age cohort, males (000s)
Brazil Prevalence of TSCI by 5-yr age cohort, females (000s)
Japan Prevalence of TSCI by 5-yr age cohort, males (000s)
Japan Prevalence of TSCI by 5-yr age cohort, females (000s)
India Prevalence of TSCI by 5-yr age cohort, males (000s)
India Prevalence of TSCI by 5-yr age cohort, females (000s)
China Prevalence of TSCI by 5-yr age cohort, males (000s)
China Prevalence of TSCI by 5-yr age cohort, females (000s)